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a b s t r a c t
Objectives: The myoepithelial cells exert important effects regulating the transition of an
in situ to an invasive carcinoma. This cell has been associated with a tumour suppressor
phenotype due to its ability to inhibit tumour growth as well as its immunomodulatory role
in cancer behaviour.
Design: In order to correlate the cancer cell growth and the role of cytokines in regulating the
neoplastic process, we have attempted to simulate an in vitro model of tumorigenesis, which
mimics a situation where in situ neoplastic cells of carcinoma are surrounded by benign
myoepithelial cells from pleomorphic adenoma. To certify the formation of in situ-like
neoplasic areas, the cells were immunostained with vimentin and AE1/AE3, markers for
tumoral benign myoepithelial cells and squamous cell carcinoma lineage, respectively. We
investigated the correlation of the cancer cell growth with the releasing of IL-4, IL-6 and IL-10
associated with the immune response. The cytokines levels were evaluated using ELISA.
Results: In in situ neoplastic areas, IL-6 amounts were higher released when compared with
IL-4 and IL-10, in all studied periods. Interestingly, the peak of IL-6 release fits with the
predominance of malignant cells in the culture.
Conclusions: The present results demonstrated that, in this in vitro condition, the myoe-
pithelial cells were not able to suppress the tumour cell proliferation even with high
secretion of IL-4 by benign myoepithelial cells which at the beginning is supposed to act
as an anti-tumour agent. In addition, these cells favoured the tumour growth by excessive
production of IL-6 and IL-10.
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The interaction between the malignant and surrounding cells
in the tumoral microenvironment is an important step in the
process of tumorigenesis. Malignant cells express growth
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Open access under the Elsevier OA license.autocrine and paracrine effects enable them to growth
autonomously, escaping from immune surveillance.1
The myoepithelial cells exert important effects regulating
the transition of an in situ to an invasive carcinoma,2 since the
myoepithelial cell layer act as a natural barrier. The
disruption of both cell layers is an absolute prerequisite for
breast tumour invasion. This cell has been associated with andic Institute and Research Center, R. Jose´ Rocha Junqueira, 13,
19 3211 3712.
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tumour growth by secretion of proteases inhibitors.3 In
addition, its immunomodulatory role in cancer behaviour
has been emphasized in many studies.2,4 There are two major
hypotheses that explain the mechanism of tumour progres-
sion from in situ to stromal tumour invasion. One is
proteolytic enzymes theory which is based on the overpro-
duction of metalloproteinases by the myoepithelial cells and
surrounding tumour cells and the other theory is known as
focal myoepithelial cell layer disruption which states that the
breast tumour invasion is a multistep mechanism which
occurs in a series of events when myoepithelial cells,
damaged by genetic abnormalities or any physical injuries,
secrete various effector molecules which alter the microen-
vironment.4,5
It is described that pro-inflammatory cytokines, chemo-
kines and adhesion molecules, regulate the sequential
recruitment of leukocytes and are frequently observed in
the tumour microenvironment6 which stimulate the growth
and survival of malignant cells.7 Although the role of cytokines
in tumour biology has been extensively studied, the literature
is still controversial about their effects on cancer biology.8
The mediators and cellular effectors of inflammation are
important components of the local tumour environment. In
some types of cancer, inflammatory conditions are present
before a malignant change occurs, whilst in other types of
cancer, an oncogenic change induces an inflammatory
microenvironment that promotes the development of
tumors.9 The mechanisms of cytokines action in carcinogen-
esis are of great importance, due to their involvement in
tumour survival. Thus, the inhibition of pro-tumorigenic
cytokine may offer an alternative target aimed at the blockage
of tumour progression.10
Interleukins (IL)-4, IL-6 and IL-10 are multifunctional
cytokines involved in adaptative and innate immunity cell
mediators. The IL-10 is an immunosuppressive molecule
secreted by tumours with anti-inflammatory action.11 The
role of IL-10 production within the tumour microenviron-
ment still remains controversial. It is debated that IL-10 can
favour tumour growth in vitro by stimulating cell prolifera-
tion and inhibiting cell apoptosis,1 which is correlated with
poor survival of some cancer patients.12,13 On the other
hand, the IL-6 is a pro-inflammatory cytokine which
modulates both the innate and adaptative immune re-
sponse.14 IL-6 has been shown to function as a growth factor
in several human tumors15–18 and plays an important role in
regulating apoptosis in many cell types. Interestingly, it has
been demonstrated that oral squamous cell carcinoma
(OSCC) patients produce increased release of IL-6 into saliva
and that IL-6 contributes to carcinogenesis of oral mucosa or
maintenance of the condition in OSCC.19 Also, it is
suggested that IL-6 inactivates p53 tumour suppressor
gene.20 In addition, IL-4 is a tumour-promoting molecule
which regulates local immune response, usually elevated in
human cancer patients.21
Thus, the purpose of this study was to determine the
expression of IL-4, IL6 and, IL-10 in an in vitro model of
tumorigenesis,22 which mimics a situation where in situ
neoplastic cells of oral carcinoma, are surrounded by benign
myoepithelial cells from pleomorphic adenoma in order tocorrelate the cancer cell growth and the role of these cytokines
in regulating the neoplastic process.
2. Materials and methods
2.1. Cell culture
Benign myoepithelial cells were obtained from explants of
pleomorphic adenoma (PA) tumours provided by surgery. In
order to validate the analysis, replicates cell culture were
obtained from three different donors according to the
methodology described in our previous study.22–24 The
squamous cell carcinoma (CAL27) was obtained from Ameri-
can Type Culture Collection (ATCC VA, USA). This study was
conducted following the approval of the Ethical Committee of
Sa˜o Leopoldo Mandic Institute and Dental Research Centre,
Campinas, Brazil (Protocol # 09/0014).
The obtained cells were cultured in Dulbecco’s modified
Eagle medium (DMEM1) (Sigma, St. Louis, MO, USA) and
supplemented with 1% antimycotic–antibiotic solution
(10,000 units of penicillin, 10 mg of streptomycin and 25 mg
of amphotericin B per ml in 0.9% sodium chloride; Sigma1),
containing 10% of donor calf serum (DCS; GIBCO1, Buffalo,
NY), plated in 60-mm diameter plastic culture dishes and
incubated under standard cell culture conditions (37 8C, 100%
humidity, 95% air, and 5% CO2) following the used protocol for
this cell lineage culture25. When both cells had reached
confluence, they were detached with 0.05% trypsin and
subcultured at a density of 110 cells/mm2 in the polystyrene
plate (96-wells), at the same time, for the following experiment.
To certify the formation of in situ-like neoplasic areas in which
neoplastic cells of squamous cell carcinoma are surrounded by
benign myoepithelial cells from pleomorphic adenoma, the
cells were examined by phase contrast microscopy, in each
studied phase (3, 5, 7, 9, 13 and 16 days after initial culture) and
also immunostained with vimentin and AE1/AE3, markers for
tumoral benign myoepithelial cells and squamous cell
carcinoma lineage, respectively. As control, the malignant
(CAL27) and the myoepithelial cells were isolated cultured and
the supernatants were collected for the following experi-
ments.
2.2. Indirect immunofluorescence
To observe the neoplasic areas formation, cells grown on
coverslips were fixed in methanol for 6 min at 20 8C, rinsed
in PBS followed by blocking with 1% bovine albumin in
phosphate buffer saline (PBS) for 30 min at room tempera-
ture. The primary polyclonal antibodies used were vimentin
(1:50, anti-rabbit, Sta. Cruz1) and AE1/AE3 (1:75, anti-mouse,
Dako1). Control staining reaction was performed using PBS
in substitution to the primary antibody. The secondary
antibodies used were Alexa Fluor 488 anti-rabbit IgG and
Alexa Fluor 594 anti-mouse IgG (Invitrogen, USA). After
washing, preparations were mounted using Vectashield1
DAPI-associated (40-6-diamidino-2-phenylindole) (Vector1)
and observed on a Zeiss Axioskop 2 conventional fluores-
cence microscope (Carl Zeiss MicroImaging GmbH,
Germany) equipped with 63 Plan Apochromatic 1.4NA
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conditions (Carl Zeiss, Oberko¨chen, Germany).
2.3. Elisa
After 3, 5, 7, 9, 13 and 16 days, supernatants from the cell
culture were harvested and centrifuged at 5000  g for 15 min
at 4 8C. Aliquots of each sample were assayed by enzymatic
immunosorbent assay (ELISA) to determine the levels of IL-4,
IL-6 and IL-10 according to the manufacturer’s recommenda-
tions (eBioscience, San Diego, CA, USA). Briefly, 100 ml of
detection antibody was added to all wells, except blank, mixed
gently and incubated overnight (16–24 h) at 4 8C. Plates were
washed 3 times and standards and supernatant were added in
the respective wells in duplicate. After the incubation time,
the plates were washed again and incubated with 200 ml of
conjugate for 60 min at room temperature. Plates were washed
3 times again and 200 ml of substrate was added and incubated
for 15 min at room temperature in the dark. The reaction wasFig. 1 – Immunostaining for vimentin in benign myoepithelial c
different periods. At 3 days (a), few small colonies of carcinoma 
cells. At 5 (b) and 7 days (c) of cell culture, the number of carcin
myoepithelial cells assuming the form of a cluster. After 9 days 
(e) and 16 days (f) of cell culture, no in situ-like area is observed
myoepithelial cell fading. Bars: (a) and (b) = 100 mm; (c)–(f) = 50 mm
legend, the reader is referred to the web version of this article.stopped by the addition of 50 ml stop solution, and colour was
measured in an automated microplate spectrophotometer
(Epoch, Biotek, Winooski, VT, USA). The total amounts of
cytokines were determined as picograms (pg/ml). Results were
calculated using the standard curves created in each assay.
The ELISA assays were carried out in a blind fashion in
triplicate.
3. Results
The morphological findings of the in situ-like neoplasic areas, in
each period, are depicted in Fig. 1. At 3 days, few small colonies
of carcinoma epithelial cells were observed surrounded by
numbered myoepithelial cells that assumed polyhedral and
stellate morphology. At 5 and 7 days of culture, the number of
carcinoma epithelial cells was more abundant assuming a
cluster forming. Moreover, after 9 days of cell culture, the
malignant epithelial cells were predominant in the plate, andells (green) and for AE1/AE3 (red) in carcinoma cells in
epithelial cells were observed surrounded by myoepithelial
oma epithelial cells is more abundant than the benign
(d), the malignant epithelial cells are predominant. After 13
 and there is malignancy predominance with the
. (For interpretation of the references to color in this figure
)
Fig. 2 – Time course of cytokine expression. Concentration of IL-4 (A), IL-6 (B) and IL-10 (C) in all analysed periods from
malignant cells co-cultured with myoepithelial cells (CAL27+MC), malignant cells alone (CAL27) or myoepithelial cells alone
(MC).
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Under the malignant cell carcinoma stimulation, the myoe-
pithelial cell assumed a spindle-shaped morphology. Almost
no myoepithelial cells were observed after the 13th day of cell
culture and after 16 days, no in situ-like area was observed and
there was a predominance of malignant cell demonstrating
that the myoepithelial cells were not able to suppress the
tumour cells blocking the malignant cell proliferation.
3.1. Cytokines measurements
The IL-6 levels were higher when compared with IL-4 and IL-10
cytokines, in all studied periods (Fig. 2). IL-6 was over
expressed since the beginning of the cell culture and reached
the peak after 9 days of cell culture (Fig. 2B). Interesting, the
peak of IL-6 release fitted with the predominance of malignant
cells in the culture when co-cultured with myoepithelial cells.
After that, the levels started to decrease mainly at 16 days.
Isolated, the myoepithelial cells released higher levels of IL-6
than the malignant cells which just produced IL-6 at the
beginning of the cell culture. On the other hand, IL-4 secretion
was the lowest in comparison with the other cytokines
(Fig. 2A). In the in situ like areas, the IL-4 secretion was
elevated at the beginning of the cell culture where was
predominant the benign myoepithelial cells. These findings
were coincident considering both cell types isolated, where IL-
4 production was higher in the myoepithelial cells than the
malignant ones. However, once the malignant cell from
squamous cell carcinoma became much more predominant
what was observed along the 9th day of cell culture, there had
been an increase of IL-4 levels which were maintained until
the 16th day. Otherwise, the IL-10 levels were maintained
continuously during the cell co-culture whereas when isolat-
ed, the myoepithelial cells produced higher levels of IL-10 than
the malignant cells, at the beginning of the experiment but at
the end, IL-10 release levels were increased in the malignant
cells.
4. Discussion
In gland tumours, especially in breast cancer, the myoepithelial
cell is considerate an important candidate for regulating the
transition of in situ carcinoma to invasive cancer.2 This
suppressor phenotype ability is associated with the productionand secretion of extracellular matrix proteins, protease
inhibitors, and various growth factors.26
In previous study, we have demonstrated that the benign
myoepithelial cells from pleomorphic adenoma stimulated by
conditioned medium from squamous cells carcinoma cells
medium, underwent phenotypic alteration represented by an
increased in growth factors contents.23,24 In this regard, in this
study we attempted to simulate an in vitro model of an in situ
arrangement, where neoplastic cells of oral squamous cell
carcinoma were surrounded by benign myoepithelial cells
from pleomorphic adenoma in order to correlate the cancer
cell growth with the releasing of IL-4, IL-6 and IL-10 associated
with the immune response.
The present results demonstrated that, in an in vitro
condition, the myoepithelial cells were not able to suppress
the tumour cells proliferation. After 16 days of cell culture, no
in situ-like area was observed and there was a predominance of
malignant cell from squamous cell carcinoma. Previous
report, considering cell competition, has shown that slowly
proliferating cells undergo apoptosis when they are sur-
rounded by fast proliferating cells.27 However, the difference
in cell growth speed alone does not always trigger cancer cell
competition.28
Tumour cells produce a variety of inflammatory mediators
including cytokines and growth factors that participate in the
formation of an important microenvironment that promote
tumour progression and dissemination.29 This tumour micro-
environment is not only composed by malignant tumour and
stromal cells but also by infiltrating inflammatory cells that in
response to tumour signals may fail to block tumour
progression, and contribute to tumour growth.30
In this present model, where the microenvironment of the
tumour was composed only by myoepithelial cells without the
inflammatory cells, we have observed that IL-6 amounts were
higher released when compared with IL-4 and IL-10, in all
studied periods. Interestingly, the peak of IL-6 release fits with
the predominance of malignant cells in the culture. Two
hypotheses may be formulated for the IL-6 levels. First one-
since the malignant cells alone synthesize very low IL-6
amount, we may infer that the myoepithelial cells enhance
the production of IL-6 by the malignant cells signalization
suggesting an importance of IL-6 in malignant tumour growth.
IL-6 is a multifunctional cytokine that is produced during a
variety of inflammatory conditions in vivo31 and also acts as a
growth factor in several human tumors16,17,32 which may
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system. Second one the IL-6 levels start to decrease mainly
after 9 days of cell culture coincidently with the decreasing of
myoepithelial cell number, corroborating the hypothesis that
IL-6 is produced mainly by myoepithelial cells, favouring the
tumorigenic activity by suppressing apoptosis.18
The IL-4 secretion levels were higher in the beginning of
the cell culture condition, where there was a predominance of
benign myoepithelial cells. However, once the malignant
cells from squamous cell carcinoma become predominant,
there was a decrease of IL-4 levels which were maintained
until the 13th day. The IL-4 has a controversial role in tumour
immunology.21 Initially reports considered this cytokine as a
potent anti-tumour agent that could be pointed out as a way
to the cancer therapy.33–35 However, clinical evidences
suggest that IL-4 is a tumour promoting molecule due to its
high level in human cancer patients favouring tumour
metastasis.36–38 In addition, IL-4 protects tumour cells from
apoptosis.21 These evidences may suggest the role of IL-4, in
this in vitro study, initially trying to control the malignant
tumour growth however, once the malignant cells become
more numerous in the ‘‘cellular battle’’, the cytokine may
exert a pro-tumorigenic action by promoting proliferation of
squamous cell carcinoma line as well as preventing cell
apoptosis.
In this proposal in vitro study, we noted a continuously level
of IL-10 in all studied periods. However, when analyzing
isolate cell culture, the higher levels are released from the
myoepithelial cell at the beginning of the cell culture. On the
other hand, at the end of the experiments, higher levels of IL-
10 release were found in the malignant cells. It is proposed
that IL-10 promotes cell proliferation and inhibits cell
apoptosis1 besides to be related to cancer immunology as
an immunosuppressive cytokine, allowing malignant cells to
escape from immune surveillance.39,40 In some reports IL-10
has been positively correlated with poor survival of cancer
patients,41 which may explain the high levels of IL-10 by the
malignant cells in the end of the experiment.
In conclusion, the present result suggests that the
myoepithelial cells, in this in vitro model, favour the tumour
growth by the production of IL-6 and IL-10. On the other hand,
at least in the beginning, the myoepithelial cells produce IL-4
probably acting as an anti-tumour agent which is not enough
to contain the malignant cell growth.
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